FDA/CDC

Lymphoma risk prompts FDA recall of Allergan’s textured breast implants

Publish date: July 24, 2019

 

Pages

Recommended Reading

FDA: 246 new reports on breast implant-associated lymphoma
Clinician Reviews
Alisertib response rate in PTCL patients was 33%
Clinician Reviews
Myeloma therapies raise cardiovascular risks
Clinician Reviews
FDA panel calls for changes to breast implant rupture screening
Clinician Reviews
Powerful breast-implant testimony constrained by limited evidence
Clinician Reviews